Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Definium Therapeutics, Inc.NASDAQ: DFTX

Total Assets · Q3 FY2026 · quarter ended Sep 2026

Total assets rises 353.4% from a year ago

Total assets stood at $1.07B at the end of Q3 FY2026, up 353.4% from a year earlier and down 3.5% from the prior quarter. Over 3 fiscal years it compounded at +37.3% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +353.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.07B-3.5% QoQ
Last fiscal yearDec 2025
$440.1M+45.7% YoY
Year agoSep 2025
$236.92M+353.4% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+353.4%——
1 year+45.7%——
3-year CAGR+37.3%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
440.1M USD
Year-over-year change
+45.7%
4-year CAGR
+28.0%

Total Assets vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +353.4% is the 4th highest of 11, against a peer median of +147.9%.
  • Over three fiscal years its annual growth of +37.3% compares with a peer median of +40.7%.
DFTX Competitors
Total Assets for DFTX and competitors
Company Period Latest balance YoY 3-year CAGR
NERVMinerva Neurosciences, Inc.Jun 2026$95.09B USD+312490.6%+21.2%
PRAXPraxis Precision Medicines, Inc.Sep 2026$1.31B USD+231.0%+101.2%
DFTXDefinium Therapeutics, Inc.Sep 2026$1.07B USD+353.4%+37.3%
AXSMAxsome Therapeutics, Inc.Jun 2026$761.45M USD+19.0%+27.7%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$497.6M USD+64.7%+153.1%
MPLTMapLight Therapeutics, Inc.Mar 2026$418.79M USD+275.4%+130.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$393.48M USD+1944.3%+144.2%
ANROAlto Neuroscience, Inc.Mar 2026$276.26M USD+60.7%+53.7%
GHRSGH Research PLCMar 2026$275.27M USD-14.1%+4.3%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$153.88M USD-40.1%-23.5%
ATHEAlterity Therapeutics LimitedDec 2025A$56.86M AUD+439.1%+3.6%
Peer median (excluding DFTX) —+147.9%+40.7%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents133.54M142.14M99.7M273.74M257.84M
Short-term Investments0000153.76M
Net Receivables00000
Inventory00000
Other Current Assets004.17M7.88M7.73M
Total Current Assets137.22M146.06M103.87M281.62M419.32M
Property, Plant & Equipment (Net)00000
Goodwill19.92M19.92M19.92M19.92M19.92M
Intangible Assets6.87M3.69M527K00
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0331K224K613K862K
Total Non-current Assets26.79M23.94M20.67M20.53M20.78M
Total Assets164M169.99M124.54M302.15M440.1M
Account Payables4.18M2.11M4.14M2.01M5.35M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.3M13.03M20.74M30.42M61.35M
Total Current Liabilities10.41M17.89M32.25M38.85M66.7M
Long-term Debt0014.13M21.85M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.93M1.18M32K041.08M
Total Non-current Liabilities1.93M1.18M14.16M21.85M41.08M
Total Liabilities12.34M19.08M46.41M60.7M107.77M
Common Stock00000
Retained Earnings(137.67M)(194.47M)(290.2M)(398.88M)(582.67M)
Accumulated OCI1.05M627K343K819K1.09M
Other Stockholders Equity00000
Minority Interest00000
Total Equity151.66M150.92M78.13M241.45M332.33M
Total Debt072K14.13M21.85M0
Net Debt(133.54M)(142.07M)(85.58M)(251.89M)(257.84M)

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.